Travere Therapeutics (TVTX)
(Real Time Quote from BATS)
$14.56 USD
-0.65 (-4.27%)
Updated Sep 23, 2024 03:16 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Travere Therapeutics, Inc. [TVTX]
Reports for Purchase
Showing records 1 - 20 ( 139 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Everyone Can Exhale Now; Filspari Full Approval Arrives in IgAN, New $19 Target
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solid Filspari Commercial Uptake Ahead Of Key Regulatory Update
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap: FILSPARI Extends Growth in U.S. IgAN Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Recap: Significant FILSPARI Growth and Momentum Bodes Well for 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FILSPARI Approved For IgAN in Europe As Expected; First Market Launch in Europe Expected in 2H24; Increasing PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
sNDA Submitted For Full Approval of FILSPARI For IgAN; Approval in Europe Expected in 2Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap: Sparsentan Receives Positive CHMP Opinion; sNDA Submission for Full U.S. Approval in 1Q24; Trim PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Flipping Forward: 4Q23 Report As Anticipated, While Filspari Launch Progresses
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NNARR Below Buyside Expects; ARR Guided Down; Is FY25E Guide at Risk?
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Travere Signs Agreement For Sparsentan in Asia; IgAN Registrational Study in Japan to Begin in 2Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E